Charles Herbaux

机构：Centre National de la Recherche Scientifique, Université de Montpellier, Centre Hospitalier Universitaire de Montpellier, Hôpital Lapeyronie, Institut de Génétique Humaine · ORCID：0000-0003-4910-476X

发表论文 304 篇 · 总被引 5196 次 · h-index 34

代表论文

• Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma (2025 · Journal of Clinical Oncology · 被引 41)
• Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3 (2025 · Blood · 被引 9)
• Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group (2025 · Blood Advances · 被引 4)
• Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO (2025 · Blood · 被引 3)
• BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real‐life study (2026 · British Journal of Haematology · 被引 1)
• Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma (2025 · Journal of Clinical Oncology · 被引 1)